Reduced C-Reactive Protein Level at Hospital Admission in Patients Treated with Tocilizumab – an Attention May Be Required

Berman, Mark; Berliner, Shlomo; Bashouti, N.; Elkayam, Ori; Ziv‐Baran, Tomer

doi:10.2139/ssrn.4263956

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been associated with improved outcomes in coronavirus disease 2019 infection and appears to be well tolerated [11][12][13]. IL-6 is the main proinflammatory cytokine resulting in C-reactive protein (CRP) generation and tocilizumab has been associated with lower CRP levels and therefore caution is recommended interpreting CRP values within the clinical context [14].…”

Section: Discussionmentioning

confidence: 99%

The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis

Desai,

Peters,

Davies

et al. 2023

eJHaem

View full text Add to dashboard Cite

Hyperhaemolysis syndrome (HHS) is a serious complication of transfusion mostly reported in patients with sickle cell disease. HHS is characterised by the destruction of both donor and autologous red blood cells. Tocilizumab is a recombinant humanised monoclonal antibody that inhibits the binding of interleukin‐6 and has been used in the treatment of severe/critical coronavirus disease 2019 infection but also some cases of HHS. We describe two further cases of HHS successfully treated with tocilizumab and propose a decision aid for when to consider this treatment.

show abstract